Brief: Gensight Biologics 9-Month Cash And Cash Equivalents At 49.1 Million Euros

Gensight Biologics SA

10/11/2021 07:44

Nov 10 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    
    * WITH OUR CURRENT FINANCIAL RUNWAY TO MID-2023, WE ARE ABLE
TO
MAINTAIN MOMENTUM BEHIND PREPARATIONS FOR LUMEVOQ'S COMMERCIAL
LAUNCH
    * CASH AND CASH EQUIVALENTS TOTALED EUR 49.1 MILLION AS OF
SEPTEMBER 30, 2021, COMPARED TO EUR 54.3 MILLION AS OF JUNE 30,
2020
    * WE SHOULD BE IN AN EXCELLENT POSITION FOR LUMEVOQ'S
EUROPEAN
LAUNCH IN FIRST HALF OF 2023
    * OPERATING CASH BURN IN Q3 OF 2021 MAINLY REFLECTS FINAL
PHARMACEUTICAL DEVELOPMENT STEPS FOR LUMEVOQ

Source text for Eikon:  ID:nBw5b8PKwa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;
+48 58 769 66 00;))